CD19-Specific T Cells Post AlloSCT

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A RearrangedRecurrent B Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory B Acute Lymphoblastic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Mantle Cell LymphomaRefractory Non-Hodgkin LymphomaRefractory Ph-Like Acute Lymphoblastic LeukemiaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ziopharm Oncology

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT03579888 - CD19-Specific T Cells Post AlloSCT | Biotech Hunter | Biotech Hunter